{"id":"abt-894","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to S1PR1, ABT-894 modulates sphingosine-1-phosphate signaling, which plays a role in various cellular processes including inflammation and immune response. This mechanism is being explored for its potential therapeutic benefits in multiple sclerosis and other autoimmune diseases.","oneSentence":"ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:27.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00507936","phase":"PHASE2","title":"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-08","conditions":"Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful","enrollment":280},{"nctId":"NCT00548925","phase":"PHASE2","title":"A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-11","conditions":"Diabetic Neuropathic Pain","enrollment":124},{"nctId":"NCT00429091","phase":"PHASE2","title":"A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-01","conditions":"Attention-Deficit/Hyperactivity Disorder, ADHD","enrollment":243}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABT-894","genericName":"ABT-894","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Relapsing multiple sclerosis, Primary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}